Neostigmine methylsulfate is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated in myasthenia gravis and has 1 investigational indication. It is grouped under the following drug class(es): Neurotransmitter agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Syntostigmin, Neostigmine methylsulphate, Proserine, Intrastigmina and Bloxiverz. Its PubChem CID is 5824.
Neostigmine methylsulfate
| CAS No | 51-60-5 |
|---|---|
| Molecular Formula | C13H22N2O6S |
| Molecular Weight | 334.39 g/mol |
| Synonyms | [3-(dimethylcarbamoyloxy)phenyl]-trimethylazanium;methyl sulfate |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Neostigmine methylsulfate is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated in myasthenia gravis and has 1 investigational indication.
The listed CAS number is 51-60-5.
The listed molecular formula is C13H22N2O6S.
The listed molecular weight is 334.39 g/mol.
[3-(dimethylcarbamoyloxy)phenyl]-trimethylazanium;methyl sulfate.
The source lists Syntostigmin, Neostigmine methylsulphate, Proserine, Intrastigmina and Bloxiverz.